Neuro-oncology
Laminar Pharmaceuticals S.A. focuses on clinical research in newly diagnosed primary glioblastoma multiforme, with interest centered on disease control and survival outcomes in aggressive brain tumours.
- Glioblastoma multiforme
- Primary brain tumours
- Central nervous system oncology
The sponsor’s clinical development activity in this area is directed toward treatment approaches for patients with newly diagnosed disease.
Oncology treatment combinations
Its research portfolio includes therapeutic combinations in glioblastoma, with attention to integration alongside established standard of care regimens used in neuro-oncology practice.
- Radiotherapy
- Temozolomide
- Combination therapy
This area reflects an interest in pairing investigational therapy with conventional cancer treatment for brain malignancies.
Survival and disease progression outcomes
Clinical research activity includes endpoints related to progression-free survival and overall survival, highlighting a focus on long-term disease management in high-grade glioma.
- Progression-free survival
- Overall survival
- RANO criteria
The sponsor’s interest lies in outcomes that track tumour progression and patient survival in a neurologic oncology setting.
Clinical development in rare and aggressive cancer
As a pharmaceutical company based in Palma, Spain, the sponsor supports multicountry clinical research in a rare and aggressive cancer population, involving collaborating sites across Europe.
- Multicentre oncology research
- Adult solid tumours
- Brain cancer clinical development
Its research footprint is concentrated on advancing therapeutic options for patients with difficult-to-treat malignant glioma.
